Send us Feedback

Hollis-Eden Pharmaceuticals (HEPH)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

HEPH » Topics » DRUG CANDIDATES IN DEVELOPMENT

These excerpts taken from the HEPH 10-K filed Mar 31, 2009.

DRUG CANDIDATES IN DEVELOPMENT

 

We are currently focusing our development activities on two compounds from our proprietary series. Our lead clinical drug development candidates are TRIOLEX™ (HE3286), a next-generation compound currently in clinical trials for the treatment of type 2 diabetes, ulcerative colitis and rheumatoid arthritis, and APOPTONE™ (HE3235), a next-generation compound in a clinical trial for late-stage prostate cancer.

 

Each of these compounds is described in more detail below. In addition, our research program, focused on adrenal hormones, has identified additional potential clinical candidates for a wide range of medical conditions.

 

DRUG CANDIDATES IN DEVELOPMENT

STYLE="margin-top:0px;margin-bottom:-6px"> 

We are currently focusing our development activities on two compounds from
our proprietary series. Our lead clinical drug development candidates are TRIOLEX™ (HE3286), a next-generation compound currently in clinical trials for the treatment of type 2 diabetes, ulcerative colitis and rheumatoid arthritis, and
APOPTONE™ (HE3235), a next-generation compound in a clinical trial for late-stage prostate cancer.

 

STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%">Each of these compounds is described in more detail below. In addition, our research program, focused on adrenal hormones, has identified additional
potential clinical candidates for a wide range of medical conditions.

 

SIZE="2">TRIOLEX (HE3286)

 

DRUG CANDIDATES IN DEVELOPMENT

STYLE="margin-top:0px;margin-bottom:-6px"> 

We are currently focusing our development activities on two compounds from
our proprietary series. Our lead clinical drug development candidates are TRIOLEX™ (HE3286), a next-generation compound currently in clinical trials for the treatment of type 2 diabetes, ulcerative colitis and rheumatoid arthritis, and
APOPTONE™ (HE3235), a next-generation compound in a clinical trial for late-stage prostate cancer.

 

STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%">Each of these compounds is described in more detail below. In addition, our research program, focused on adrenal hormones, has identified additional
potential clinical candidates for a wide range of medical conditions.

 

SIZE="2">TRIOLEX (HE3286)

 

DRUG CANDIDATES IN DEVELOPMENT

STYLE="margin-top:0px;margin-bottom:-6px"> 

We are currently focusing our development activities on two compounds from
our proprietary series. Our lead clinical drug development candidates are TRIOLEX™ (HE3286), a next-generation compound currently in clinical trials for the treatment of type 2 diabetes, ulcerative colitis and rheumatoid arthritis, and
APOPTONE™ (HE3235), a next-generation compound in a clinical trial for late-stage prostate cancer.

 

STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%">Each of these compounds is described in more detail below. In addition, our research program, focused on adrenal hormones, has identified additional
potential clinical candidates for a wide range of medical conditions.

 

SIZE="2">TRIOLEX (HE3286)

 

EXCERPTS ON THIS PAGE:

10-K (4 sections)
Mar 31, 2009

RELATED TOPICS for HEPH:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki